[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100599733":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":30,"locations":26,"responsibleParty":36,"collaborators":26,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":26,"eligibilityCriteria":46,"healthyVolunteers":42,"sex":47,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":26,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":61,"overallStatus":64,"whyStopped":26,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":26},{"fullName":5,"class":6},"Alexandria University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Pentoxifylline group","ACTIVE_COMPARATOR","They will be given pentoxifylline as reno-protective drug (trentoximal, Egypharma ; E.D.A Reg.No.: 25276\u002F2007) was administered intravenously to Neonates with perinatal hypoxia at 5mg\u002Fkg\u002Fhr given over 6 h daily for 3 consecutive days",[13],"Drug: Pentoxifylline",{"label":15,"type":16,"description":17,"interventionNames":18},"Control group","PLACEBO_COMPARATOR","They will not be given pentoxifylline as reno-protective drug",[19],"Other: placebo distilled water",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Pentoxifylline","Intravenous administration for 3 days",[9],null,{"type":6,"name":28,"description":24,"armGroupLabels":29,"otherNames":26},"placebo distilled water",[15],[31],{"name":32,"role":33,"phone":34,"phoneExt":26,"email":35},"Marwa M Farag, PhD","CONTACT","01288681788","d.marwa.farag@gmail.com",{"type":37,"investigatorFullName":38,"investigatorTitle":39,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Marwa Mohamed Farag","Assistant professor of Pediatrics","100599733","nephroprotection-following-perinatal-asphyxia-randomized-controlled-trial-100599733",false,"NCT07088328","Nephroprotection Following Perinatal Asphyxia: Randomized Controlled Trial","Effect of Pentoxyphylline in Nephroprotection Following Perinatal Asphyxia: Randomized Controlled Trial","Inclusion Criteria:\n\nInclusion criteria:\n\n1. Evidence of perinatal hypoxia, as indicated by at least one of the following:\n\n   1. Apgar score of less than or equal to 5 at 10 minutes.\n   2. ongoing resuscitation at 10 minutes.\n   3. pH less than 7.14 or a base deficit worse than or equal to minus 12 mmol\u002FL on cord\u002Farterial\u002Fvenous\u002Fcapillary blood gas obtained within 60 minutes of birth.\n2. Evidence of moderate to severe encephalopathy using Sarnat staging score.(14)\n3. Greater than or equal to 35 weeks gestational age.\n4. Birth weight greater than or equal to 1800 g.\n\nExclusion Criteria:\n\nNeonates with any of the following will be excluded:\n\n1\\. Birth weight less than 1800 g. 2. Major congenital malformations\u002Fchromosomal anomalies including major cardiac anomalies. 3. Preterm less than 35 weeks gestational age according to modified Ballard score. (15) 4. progressive neuromuscular disorders (eg spinal muscle atrophy). 5. Severe systemic infections (eg TORCH infection).\n\n\\-","ALL","1 Hour","5 Days",{"count":51,"type":52},30,"ESTIMATED","INTERVENTIONAL",[55],"NA","The aim of this study is to determine the value of Pentoxifylline for nephroprotection in these neonates with perinatal asphyxia, using cystatin C, regional oxygenation measured near infrared spectroscopy and renal Doppler sonography.",[58,59,60],"Hypoxic-Ischemic Encephalopathy","Neonatal Encephalopathy","Pentoxifylline Adverse Reaction",[62,63],"preterm infants","nephroprotection","NOT_YET_RECRUITING","2025-07-19",{"date":67,"type":68},"2025-07-28","ACTUAL",{"date":70,"type":52},"2025-07-30",{"date":72,"type":52},"2026-03-02",{"name":5,"class":6}]